Joshua Remland

Also affiliated with Dana-Farber Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma”.

Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma

Nature Communications(2024)10.1038/s41467-024-51271-3

N/A

0.654DataRank · unranked

17 citations

Kristen E. Lowder, Kevin S. Kapner, Ronan J. Kelly, Hui Zheng, Nadine J. McCleary +20 more

Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor

Cancer Immunology Research(2024)10.1158/2326-6066.cir-23-1073

N/A

0DataRank · unranked

28 citations

Andressa Dias Costa, Emily Kawaler, Victoire Cardot‐Ruffino, Osama E. Rahma, Nina Beri +36 more